Skip to main content
OpenTrials
Completed

NCT Number: NCT00186810

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

This protocol studied the effect of administration of a myeloablative pretransplant preparative regimen followed by an infusion of donor stem cells in children with severe sickle cell disease. The donor graft consisted of bone marrow or cord blood derived from a genetically matched sibling.

The primary aim of the study was to evaluate how well the donated cells migrated to the bone marrow and begin producing healthy red blood cells, white blood cells and platelets (engrafted), how well the recipients immune system recovered, and assess any regimen related toxicities including a potentially life-threatening transplant related complication called graft-versus-host-disease or GVHD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

About this study

The secondary objectives of this protocol evaluated the effect of this transplant procedure on the subsequent clinical course of patients with severe SCD. Specifically, to determine whether pre-transplant organ dysfunction (brain, heart, lung, kidney, liver, spleen, etc) resultant from sickle hemoglobinopathy can be reversed following this particular transplant procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of severe' disease is denoted by one of the following:

  • Previous central nervous system vaso-occlusive episode with or without residual neurologic findings or
  • Frequent painful vaso-occlusive episodes with significant interference with normal life activities and which necessitates chronic transfusion therapy or
  • Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.

Exclusion criteria

  • Patient with SCD chronic lung disease greater than or equal to stage 3
  • Patient with severe renal dysfunction defined as creatinine clearance < 40 ml/min/1.73m2.
  • Patient with severe cardiac dysfunction defined as echocardiogram shortening fraction < 25%.
  • Patient with HIV infection.
  • Pregnant or lactating.
  • Patient with unspecified chronic toxicity that in the opinion of the Principal Investigator is serious enough to detrimentally affect the patient's capacity to tolerate SCT.
  • Patient or patient's guardian(s) unable to understand the nature and risks inherent in the BMT process

Treatment and study plan

Busulfan, Cyclophosphamide, Horse ATG

Drug

Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.

Allogeneic stem cell transplant

Procedure

Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant

Primary outcomes

  1. To evaluate engraftment, GVHD, hematopoietic and immune reconstitution, and regimen-related mortality and morbidity in patients with severe sickle cell disease undergoing transplant using either HLA matched sibling bone marrow or cord blood grafts.

    Time frame: March 2007

Sponsors and collaborators

Lead sponsor

St. Jude Children's Research Hospital

Other

Registry information

Official study title

Allogeneic Stem Cell Transplantation From HLA/MLC Genotype Identical Donors for Patients With High Risk Sickle Cell Disease

Important dates

Study start
1992
Primary completion
2006
Study completion
2007
First posted
Sep 16, 2005
Registry last updated
May 29, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.